目的:研究"黄金菊"抗甲型流感病毒PR8(A/PR8/34/H1N1)的活性,为药效组分中药的发现提供科学依据.方法:采用MTT掺入比色法测定药效组分中药"黄金菊"对狗肾传代细胞(MD-CK)的毒性及对PR8的有效性,同时设定阳性药物对照组及空白对照组;采用生物效价二剂量法对该药物与阳性药物的等效剂量进行比较.结果:该药物对MDCK细胞的TD50为1.9061mg·mL-1;TD0为0.625mg·mL-1;对流感病毒PR8的MIC为312.5μg·mL-1,IC50为112.8694μg·mL-1.双黄连粉针与"黄金菊"等反应剂量比为184.91%;病毒唑与"黄金菊"等反应剂量比为46.17%.结论:"黄金菊"具有对甲型流感病毒的直接抑制作用,且存在明显的量效反应关系,作用优于市场应用较广泛的双黄连粉针,开发前景广阔.

The anti-influenza effect of Huangjinju, a Chinese medicine with active components alignment, was studied to provide scientific evidence for the discovery of new Chinese medicines. The anti-influenza effect of Huangjinju and its toxicity to MDCK were determined by the MTT assay. Meanwhile, the blank control and positive control were established. The equivalent-dose ratio of Huangjinju to positive drugs was estimated by the two-dose method. In MDCK, Huangjinju was found to inhibit influenza H1N1 virus in a concentration-dependent manner, with TD50 being 1.9061mg·mL-1, TD0 0.625mg·mL-1, MIC 312.5μg·mL-1 and IC50 112.8694μg·mL-1. The equivalent-dose ratio of Shuanghuanglian to Huangjinju was 184.91%, and that of Virazole to Huangjinju was 46.17%. The results showed that, compared with Shuanghuanglian, Huangjinju has direct inhibitory effect on H1N1 influenza virus. With an obvious dose-effect relationship, Huangjinju will have a bright prospect.

科技部科技基础性工作专项重点项目(2007KYI130100):道地中药材及标准物质研制与分析方法研究，负责人：张贵君。